Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma - Wikidata - wikimedia - TriplyDB

Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma

Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma

http://www.wikidata.org/entity/Q37712557

about

Structural basis for pure antagonism of integrin αVβ3 by a high-affinity form of fibronectin The clearance of dying cells: table for two Mechanotransduction and extracellular matrix homeostasis Pathophysiology of systemic sclerosis αv integrins: key regulators of tissue fibrosis Recent advances in the genetics of systemic sclerosis: toward biological and clinical significance Animal models of systemic sclerosis: their utility and limitations.Prestress in the extracellular matrix sensitizes latent TGF-β1 for activation.Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.Pivotal Functions of Plasmacytoid Dendritic Cells in Systemic Autoimmune Pathogenesis.Altered MCM protein levels and autophagic flux in aged and systemic sclerosis dermal fibroblasts Fibrillin microfibrils in bone physiology.Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms.mTOR inhibition rescues osteopenia in mice with systemic sclerosis.Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts.Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis.Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis Myofibroblasts in murine cutaneous fibrosis originate from adiponectin-positive intradermal progenitors.Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients The matrix protein Fibulin-5 is at the interface of tissue stiffness and inflammation in fibrosis.Origin of fibrosing cells in systemic sclerosis.Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis Fibrillin-containing microfibrils are key signal relay stations for cell function.Update on macrophages and innate immunity in scleroderma Rational design of a protein that binds integrin αvβ3 outside the ligand binding site.ADAMTS-10 and -6 differentially regulate cell-cell junctions and focal adhesions.Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis.αvβ1 integrin as a novel therapeutic target for tissue fibrosis.A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.Cardiovascular manifestations in Marfan syndrome and related diseases; multiple genes causing similar phenotypes.Molecular and cellular basis of scleroderma.Transforming growth factor β--at the centre of systemic sclerosis.Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.Early systemic sclerosis-opportunities for treatment.Matrix remodeling in systemic sclerosis.The role of the acquired immune response in systemic sclerosis.A healthy tension in translational research.Critical Appraisal of the Utility and Limitations of Animal Models of Scleroderma.Unifying mechanism for different fibrotic diseases.Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis.

P2860

Q24292863-E6387C5D-23BB-4068-892A-0F6B2BE845F9 Q26753825-3CAE26A1-FBCE-4EC3-8DE1-8125FC33A245 Q26998075-7485E9E7-3A76-4318-9A5F-33677F230826 Q28072568-47142739-89B6-4D2C-AE66-E660A23FA472 Q28076205-878889D1-360F-4A6A-9E49-C7E2D266E2BA Q28088499-53245D53-7E69-4259-B6F0-FE9ACB451C34 Q28390528-B2F51489-DBE1-48FA-B63D-337A34C2F5D7 Q30596295-8A666772-EE9D-4407-B894-9FC91272030C Q33840143-BA03E4BA-04A2-408F-9D28-28C881AEE4C2 Q33956662-4C24AA9B-3CD4-47A8-AC6B-DC6BDE0D2FA6 Q34000514-275CB3D3-D4C9-4AF6-9D97-3316229A97D2 Q34495815-87A6BD00-C51F-492D-BD5C-98B9FE680CEB Q34888501-106C11CE-4CAA-4837-BBDB-6F1D0317E940 Q34924612-B838C166-763B-4A19-97DF-E8C9433BC54C Q34995163-A0086EE6-A849-4AA0-BBF7-6CAF91472992 Q35113804-0A5E818C-A557-40C7-96ED-DC2830A4DD5F Q35545185-F31C35EF-2986-4C01-AB30-A2C4E45D8354 Q35755610-4E79F46C-11D0-4052-BF67-3C7AAA07626C Q36040200-47C70E35-7FF1-4284-A3D3-03D4D6103380 Q36251455-7D8B3A13-2F52-4AB0-B386-F6897DB5F49D Q36264658-8DD68DDC-A32B-46B0-9134-07E0E3A6642D Q36266550-9F5D351C-2C44-4666-A3D2-64E07AE0766C Q36470965-87F7C4F5-64D4-43FC-843D-938A9A1EE915 Q36607887-8AC69A7B-0B30-457F-BE79-3812F2DD411D Q36974007-BAB1885F-1F03-4F33-BDBB-C4C89D2166C7 Q37363956-453D9931-ACCC-4BD9-876E-BA2CB43EC3BB Q37395851-D03A2CD7-D1E8-4479-989C-2C3FE50BDE61 Q37410984-482A262E-6E50-4FED-917B-76DFA9200B42 Q37717578-F6A2040F-0D01-43D6-AC3B-CD4157FDDFFF Q38215407-D560A2FB-8950-4D57-9461-F085480B9B46 Q38230276-54C15BCB-8EAA-4532-B7EB-D3A482712D0C Q38241227-D259745A-CC14-41BC-A3A8-CD4D0F903FD2 Q38269966-A1AFB37B-849E-4DB2-BBE2-4AD7BD6A597A Q38364855-A929CC91-1FB7-468F-A147-52A28CE64575 Q38542590-BD4CEEEB-C7DF-4E39-BD26-962E361C8BCB Q38543690-0B7520A6-9D0A-4DF0-BA85-259BA702460E Q38592372-03AADFE3-8A25-465D-9C72-A8428D30CD85 Q38681751-B662F37C-F43B-4474-8664-EA8F5E566823 Q38829704-E872A189-EB0F-40F0-8F1F-9B79820EDBA3 Q38956376-4BE100D2-5ACF-4D5E-A6C3-9CE0A6A465D9

P2860

Integrin-modulating therapy prevents fibrosis and autoimmunity in mouse models of scleroderma

http://www.wikidata.org/entity/Q37712557

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 October 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Integrin-modulating therapy pr ...... in mouse models of scleroderma

@en

Integrin-modulating therapy pr ...... n mouse models of scleroderma.

@nl

type

label

Integrin-modulating therapy pr ...... in mouse models of scleroderma

@en

Integrin-modulating therapy pr ...... n mouse models of scleroderma.

@nl

prefLabel

Integrin-modulating therapy pr ...... in mouse models of scleroderma

@en

Integrin-modulating therapy pr ...... n mouse models of scleroderma.

@nl

P1433

Q37712557-03793936-F158-40AA-AB56-362BF1C2AB96

P1476

Q37712557-CEB15633-B137-43A5-8E9A-0CE3F35A3BDC

P2093

Q37712557-13FDE0ED-AFE1-4B81-8309-9E6658C7BABF

Q37712557-72C98D69-9A85-4F5A-8ADC-49B13050D2ED

Q37712557-7D7573D6-DDB2-49D0-BDAA-34BF21F691F0

Q37712557-81F3DCF2-76EA-41EA-AB35-6D5F900CF4EC

Q37712557-8470EB29-79B4-4DC5-9EC8-2FD4D43B8ED9

Q37712557-962C4178-664D-4325-890A-428956BFCF31

Q37712557-A88C2EA6-5F6B-4ACB-8E6C-7CE31163062A

P2860

Q37712557-044E1C6D-8F7A-4BBC-990C-866DD93795C0

Q37712557-1284CAFB-873F-4099-84B3-0FBAD9CB7ABE

Q37712557-12F2B12D-52E8-4997-9996-B0A007618C78

Q37712557-1AA60B36-74C8-445E-A770-FC96C7F2CDBF

Q37712557-234DFB75-9054-4BA5-B0E2-CD79D71ABF1A

Q37712557-2D6532D0-804E-4980-BCD8-94FC65BE3AEB

Q37712557-45640785-8FD3-4ADA-AA15-0CFA251A4A75

Q37712557-576580C7-1458-471B-8D16-4516D15A8BC0

Q37712557-57B76AE7-DA38-47B7-B086-1F8746972939

Q37712557-5EF579E1-0FE2-4954-B63A-D54F9C36DCDE

P2888

Q37712557-1D80B145-272A-458E-B21D-B66FB6450838

P304

Q37712557-6D5B10B4-9B4A-4219-866A-3843FC4D9512

P31

Q37712557-9B51B619-131E-46C5-A78C-C4E35009CA56

P356

Q37712557-81E8A6D3-E513-4D03-9AAF-05F6ADFA2083

P407

Q37712557-B0E1A28F-C1A2-47FB-8C2B-99916ABB5D8C

P433

Q37712557-5508CE17-1764-47F7-A022-C0F1967DB20F

P478

Q37712557-C2FD5939-9EF9-4E30-A7F2-AD27D67E33C6

P577

Q37712557-8FE39DCF-34FE-4B67-8A7C-61039C3CB849

P5875

Q37712557-3B6B082D-1136-4A09-9AF3-985F48A9355C

P6179

Q37712557-1C60A9C6-1B32-44C8-B6FB-F378E450D3BB

P698

Q37712557-49E0D707-B576-4A0D-B2FC-972CEE446139

P932

Q37712557-1C2E05D2-49F0-42ED-B11C-2B975100F6D7

P356

P1433

P1476

Integrin-modulating therapy pr ...... in mouse models of scleroderma

@en

P2093

David L Huso

http://www.w3.org/2001/XMLSchema#string

Elaine C Davis

http://www.w3.org/2001/XMLSchema#string

Elena M Gallo

http://www.w3.org/2001/XMLSchema#string

Elizabeth E Gerber

http://www.w3.org/2001/XMLSchema#string

Fredrick M Wigley

http://www.w3.org/2001/XMLSchema#string

Harry C Dietz

http://www.w3.org/2001/XMLSchema#string

Stefani C Fontana

http://www.w3.org/2001/XMLSchema#string

P2860

Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome

Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6

IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells

Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis

Rac recruits high-affinity integrin alphavbeta3 to lamellipodia in endothelial cell migration.

Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?

CCN2 is required for the TGF-β induced activation of Smad1-Erk1/2 signaling network

Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.

Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome.

P2888

P304

126-130

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE12614

http://www.w3.org/2001/XMLSchema#string

P407

P433

7474

http://www.w3.org/2001/XMLSchema#string

P478

503

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257598308

http://www.w3.org/2001/XMLSchema#string

P6179

1008131344

http://www.w3.org/2001/XMLSchema#string

P698

24107997

http://www.w3.org/2001/XMLSchema#string

P932

3992987

http://www.w3.org/2001/XMLSchema#string